No Data
Cognition Therapeutics to Report Biomarker Results From Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025
Buy Recommendation for Cognition Therapeutics: Promising Phase 2 Results and Strategic Focus on Alzheimer's and Dementia Indications
Cognition Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Cognition Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $5 From $6
Chardan Capital Maintains Buy on Cognition Therapeutics, Lowers Price Target to $8
Cognition Therapeutics Analyst Ratings
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
